Recurrent Esophageal Cancer Completed Phase 1 Trials for Cetuximab (DB00002)

IndicationStatusPhase
DBCOND0028797 (Recurrent Esophageal Cancer)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00397384Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerTreatment